Most Awaited Q3 Sale is back. Upto 30% discount on every report.

Fiducial Markers Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 March 24
SKU : MI1830
180 pages
Report Summary
Table of Contents
List of Tables and Figures

Fiducial Markers Market is segmented By Product Composition (Gold Markers, Polymer Markers, Carbon Markers, Platinum Markers, Liquid Markers, Others), By Application (Radiation Therapy Guidance, CT and CBCT Scans, MRI and MEG Scans, PET Scans, Endoscopic Ultrasound Scans, Others), By Placement Location (Head and Neck, Breast, Lung, Abdomen, Prostate, Others), By End-Users (Hospitals, Ambulatory Surgical Clinics, Specialty Clinics, Research Institutions), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030


Fiducial Markers Market Report Overview

The fiducial markers market report provides an analysis of the market size, current trends, competitive landscape, and future market outlook. The demand for fiducial markers is increasing due to the growing prevalence of cancer and the increasing adoption of radiation therapy. The market is witnessing a surge in demand from developed countries such as the United States and Europe. The competitive rivalry is intensifying with major players such as CIVCO Radiotherapy, IZI Medical Products, and others actively operating in the market.

Fiducial markers also referred to as fiducials, are tiny metal implants that are inserted into the body of a patient using a fine needle to direct radiation therapy. They are roughly 3 mm in size. The markers themselves are not uncomfortable, and the patient cannot feel them internally. Patients receiving external beam radiation therapy for prostate cancer are the ones who use fiducials the most frequently. They can, however, also be utilized to direct treatment for additional soft tissue cancer types, such as lung, head, and neck tumors.

Floriculture Market Scope and Summary



Market CAGR


Segments Covered

By Product Composition, By Application, By Placement Location, By End-Users, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America


To Get a Free Sample Click here


Fiducial Markers Market Dynamics and Trends

The major factors driving the global fiducial markers market are the rising demand for fiducial manufacturers due to a rapid rise in cancer incidences, the market's expansion is being further fuelled by the increased awareness of radiation, rising demand for medical imaging procedures, and rising healthcare expenditure in emerging markets.

Rising demand for fiducial manufacturers due to a rapid rise in cancer incidences is expected to drive the market’s growth.

According to World Health Organization, in 2022, nearly 10 million deaths, or nearly one in six deaths, will be caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. In low- and lower-middle-income nations, cancer-causing infections, including the human papillomavirus (HPV) and hepatitis, are thought to cause 30% of cancer cases. If caught early and appropriately treated, many tumors are curable.

And according to National Cancer Institute(U.S.A), in the U.S., there will likely be 1,806,590 new cases of cancer diagnosed in 2020, and there will also likely be 606,520 cancer-related deaths. The most prevalent cancers are breast cancer, lung, and bronchus cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer (listed in descending order by estimated new cases in 2020). The market is driven by the possibility for the fiducial producers to identify the tumor due to the rise in cancer incidence.

The complications caused by the products are projected to impede the growth of the market.

Fiducial markers have made for the most effective drug delivery to tumors while causing the least amount of damage to surrounding healthy tissues. Fiducial markers have certain additional risks, although having a major benefit in radiation therapy procedures.

Pneumothoraces and pulmonary bleeding were the most frequent side effects. The risk of problems was found to be higher when FM implantation and biopsy sampling were done simultaneously. Lung lesions accounted for the majority of the issues, and all FM implantations for lung lesions were performed under CT guidance. Self-limiting pneumothoraces, pulmonary bleeding, and hemoptysis were among the less severe issues. The most severe side effect was pneumothorax, which necessitated medical attention and hospitalization. 

COVID-19 Impact on Fiducial Markers Market Growth

Due to strong lockdown procedures and a restricted flow of personnel, the COVID-19 virus epidemic has had a minimal impact on the fiducial markers sector. The current coronavirus pandemic has harmed healthcare. The COVID-19 pandemic has had a huge influence on the market for fiducial manufacturers as well as on the world's healthcare systems. According to an article in Cancer Connect 2020, researchers from the Dana Farber Cancer Institute found that the six most frequent cancer types—breast, colorectal, lung, pancreatic, gastric, and esophageal cancers—had a 46% decline in diagnoses during the COVID-19 pandemic.

Additionally, it was advised to delay elective surgeries, cancer screenings, and other health prevention services unless the risks outweighed the benefits and to prepare the hospital infrastructure for the care of COVID-19 patients by the Centers for Disease Control and Prevention (CDC) and many other medical professional organizations. The COVID-19 epidemic has thus damaged the market for fiducial producers. However, it is anticipated that things will get better with time. Major healthcare corporations are stepping up their attempts to find potential COVID-19 vaccines and medications, putting tremendous strain on hospital infrastructures worldwide. Despite this, ongoing cancer treatments have kept the market for fiducial markers strong. However, several of the procedures were rescheduled or abandoned.

Fiducial Markers Market Segment and Shares

The gold fiducial markers segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

The gold fiducial markers segment is the highest market holder in the global fiducial markers market. Gold fiducial markers can also be combined with other metals like titanium, platinum, and nickel for increased effectiveness. For instance, these markers improve visibility in MRI scans when coupled with titanium stripes. Major businesses are increasing their R&D spending to create more efficient products. As an illustration, IBA Dosimetry GmbH introduced the Visicoil linear pure gold fiducial marker, a novel helical-shaped product with a hollow core that lowers the incidence of typical issues such as marker migration and artifacts.

Additionally, in June 2022, Nanovi reported that its liquid fiducial marker, BioXmark, has demonstrated in a clinical study to be technically possible to implant in stomach cancer patients to guide preoperative image-guided radiation therapy (IGRT). It can be difficult to accurately identify the treatment target on daily collected CBCT scans during preoperative IGRT of the stomach. Twelve (12) patients with stomach cancer participated in this clinical investigation from the Amsterdam University Medical Center. The study's objective was to evaluate the technological viability of implanting liquid marker (BioXmark) and gold marker (Visicoil) for preoperative stomach cancer IGRT guidance. The segment drives the market as a response.

Fiducial Markers Market Geographical Analysis

North America holds the largest market share in the global Fiducial Markers market.

North America dominates the global fiducial markers market primarily due to its large population, excellent medical infrastructure, and high-income levels. Due to factors such as the rising incidence of cancer, the presence of numerous major players, rising spending on research and development, increasing patient awareness and preference for radiotherapy, favorable reimbursement laws, and technological advancements, North America is anticipated to account for a sizeable portion of the global market for fiducial markers. 

The American Association for Cancer Research reports that since the 1990s, the age-adjusted total cancer death rate in the U.S. has been consistently falling. The decrease between 1991 and 2019 means avoiding over 3.5 million cancer deaths. As of January 1, 2022, more than 18 million cancer survivors will live in the U.S., an increase of more than a million over the previous three years. The advancements in the fight against cancer have not benefited all American communities equally.

It'll also increase the need for disease treatment and grow the market. In North America, the U.S. holds the largest proportion of the market for fiducial markers. The Fiducial Markers Market in this area is also anticipated to benefit from cutting-edge radiation techniques, imaging modalities, and well-established healthcare infrastructure.

Fiducial Markers Companies and Competitive Landscape

The Fiducial Markers market is moderately competitive with local and global companies’ presence such as Boston Scientific Corporation, Medtronic Plc, Nanovi A/S, IBA Dosimetry, Roper Technologies Inc., Guerbet SA, Eckert & Ziegler BEBIG S.A., IZI Medical Products Inc., Naslund Medical AB, and MediTron SA and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in May 2022, the first Prostate Cancer treatments use Nova Fiducial Markers announced by C4 Imaging. The first prostate cancer therapies using Nova, a multimodality fiducial marker created to improve the precision of cancer treatment, have been announced by C4 Imaging LLC. 

Boston Scientific Corporation.

Overview: A medical technology company called Boston Scientific Corp. (Boston Scientific) is engaged in the development, production, and commercialization of devices for several interventional medical specialties. Electrophysiology, gastroenterology, gastrointestinal surgery, female pelvic medicine, gynecology, interventional cardiology, interventional radiology, neurological surgery, orthopedic surgery, pain management, pulmonology, urology, and vascular surgery are among the specialties in which the company sells products. All across the world, Boston Scientific provides services to hospitals, clinics, outpatient facilities, and medical offices.

Product Portfolio:

LumiCoil PlatinumFiducial MarkersLumiCoil Platinum Fiducial Markers feature platinum construction designed for clear visibility in CT, X-Ray, EUS, CBCT, and MRI procedures. The use of fiducials may lead to more accurate targeting in the delivery of radiation.

The global Fiducial Markers market report would provide access to approx.: 45+market data table, 40+ figures, and 200 (approximate) pages.


Trending Topics

Pet Medication Market

Esoteric Testing Market

C-Arms Market

Biomarkers Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy
Request new version
What is the Projected CAGR value of the Fiducial Markers Market?
Fiducial Markers Market is expected to grow at a high CAGR during the forecasting period 2023-2030.
Which region controlled the global market during 2023-2030?
North America region Controls the Fiducial Markers Market during 2023-2030.
Which is the fastest growing region in the Fiducial Markers Market?
Among all regions, Asia Pacific is the fastest-growing market share during the forecast period.
Who are the key players in the Fiducial Markers Market?
Boston Scientific Corporation, Medtronic Plc, Nanovi A/S, IBA Dosimetry, Roper Technologies Inc., Guerbet SA, Eckert & Ziegler BEBIG S.A., IZI Medical Products Inc., Naslund Medical AB, and MediTron SA and more.